Uncategorized
Tyrogenex Initiates the APEX study, a Phase 2 Trial of Oral Treatment with X-82 for Wet AMD
PALM BEACH GARDENS, Fla.--(BUSINESS WIRE)--Tyrogenex, privately held company focused on the development of next-generation targeted therapeutics for cancer and ophthalmology, announced the initiation of a phase 2 study referred to as "APEX."
